Comparative Risk of Cancer Recurrence During Treatment With Biologics: A Meta-Analysis

Daniel Isufi, Christopher Willy Schwarz, Mikkel Bak Jensen, Jakob Seidelin, Lone Skov, Nikolai Loft · 2026

Read Comparative Risk of Cancer Recurrence During Treatment With Biologics: A Meta-Analysis by Daniel Isufi, Christopher Willy Schwarz, Mikkel Bak Jensen, Jakob Seidelin, Lone Skov, Nikolai Loft (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625878.txt.

Description

Daniel Isufi and co-authors weigh cancer risk in a 2026 meta-analysis on biologic drugs. People with immune-driven inflammatory diseases who have already had cancer pose a dilemma: biologic labels urge caution, and trials excluded them, yet stopping effective treatment carries its own costs.

Earlier work compared biologics with older systemic drugs, a design open to bias. This review instead compares biologic against biologic. Four studies covering several hundred patients were pooled with random-effects methods, contrasting tumor necrosis factor inhibitors with other biologic classes. The analysis asks whether any biologic family stands out as safer for cancer survivors.

Catalog record

CREATORDaniel Isufi, Christopher Willy Schwarz, Mikkel Bak Jensen, Jakob Seidelin, Lone Skov, Nikolai Loft
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13625878

Browse the full library · About the Tower of Babel